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Abstract
 
Cytogenetic analysis is useful in the diagnosis and to assess prognosis of B-cell chronic lymphocytic leuke-
mia (B-CLL). However, successful cytogenetics by standard techniques has been hindered by the low in
vitro mitotic activity of the malignant B-cell population. Fluorescence in situ hybridization (FISH) has be-
come a useful tool, but it does not provide an overall view of the aberrations. To overcome this hurdle, two
DNA-based techniques have been tested in the present study: comparative genomic hybridization (CGH)
and amplotyping by arbitrarily primed PCR (AP-PCR). Comparative genomic hybridization resolution de-
pends upon the 400-bands of the human standard karyotype. AP-PCR allows detection of allelic losses
and gains in tumor cells by PCR fingerprinting, thus its resolution is at the molecular level. Both tech-
niques were performed in 23 patients with stage A B-CLL at diagnosis. The results were compared with
FISH. The sensitivity of AP-PCR was greater than CGH (62% vs 43%). The use of CGH combined with
AP-PCR allowed to detect genetic abnormalities in 79% (15/19) of patients in whom G-banding was not
informative, providing a global view of the aberrations in a sole experiment. This study shows that com-
bining these two methods with FISH, makes possible a more precise genetic characterization of patients
 
with B-CLL. © 2001 Elsevier Science Inc. All rights reserved.
 
1. Introduction
 
The pathogenic events in chronic B-cell lymphocytic
leukemia (B-CLL), the most common form of adult leuke-
mia in Western countries, remains poorly understood.
B-CLL is a malignancy of self-reactive, activated CD5
 

 
 B
cells devoted to the production of polyreactive natural au-
toantibodies [1]. The clinical course of this disease is ex-
tremely variable; some patients survive only a few months
whereas others have stable disease greater than 10 years [2].
Rai and Binet clinical staging systems are useful prognostic
tools. However, they do not distinguish which patients in
early stages of the disease will progress. Other prognostic
parameters, e.g., short lymphocyte doubling time and/or dif-
fuse bone marrow infiltration are known risk factors for
progressive disease in early-stage CLL [2,3]. Although pa-
tients lacking these features have a low risk for disease pro-
gression, 10–15% of such cases will still progress within 5
years of diagnosis, emphasizing the need for additional
prognostic factors in early CLL [3,4].
Genetic studies have provided useful information in
understanding the pathogenesis of CLL, and some aberra-
tions may also have a prognostic impact [4–10]. In CLL, ac-
curate and successful cytogenetic analysis has been hin-
dered by the low in vitro mitotic activity of the critical
B-cell population with metaphases arising from normal T-cells
being frequent. Thus, G-banding analysis is informative in
only a minority of cases. Although FISH has become a use-
ful tool and, in some studies, showing to be informative in
up to 80% of cases [10], it does not provide a global view of
the chromosomal aberrations. Two molecular techniques
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that are not cell-growth based, comparative genomic hy-
bridization (CGH) and amplotyping by arbitrarily primed
PCR (AP-PCR), have been recently introduced and applied
to study genetic abnormalities in human malignancies. CGH
allows tumor genomes to be tested for the presence of chro-
mosomal unbalances without the need of metaphases and
only requires small numbers of tumor cells to prepare DNA
[11]. The resolution of this technique depends upon the 400-
bands of the human standard karyotype. AP-PCR is a mo-
lecular karyotyping (amplotype) approach which under con-
trolled conditions allows to estimate quantitative changes in
DNA content (allelic losses and gains) in tumor cells rela-
tive to normal tissue from the same cancer patients [12].
This study aimed to investigate the value of CGH and
AP-PCR to detect chromosomal abnormalities in B-CLL
and compares their sensitivity with FISH. Both techniques
were performed in diagnostic samples from 23 patients with
stage A B-CLL, the majority (19 cases) with normal karyo-
type or not available metaphases. B
 
2. Materials and methods
 
Twenty-three patients with stage A B-CLL from whom
DNA was available at diagnosis were studied. All patients
showed lymphocytosis with morphological and immu-
nophenotypical features consistent with B-CLL (CD5
 

 
,
CD19
 

 
, CD23
 

 
). The definition of atypical morphology
was based on the FAB classification of CLL. Table 1 sum-
marizes the main disease features. Five patients had disease
progression: two died due to the disease-related cause, and
three required treatment because of progressive disease.
Cytogenetic studies by conventional methods were car-
ried out in bone marrow cells. Two cultures were estab-
lished from each sample: one with a B-cell mitogen
(pokeweed) and one without mitogens. Clonal abnormali-
ties were described according to the ISCN [13]. Out of 23,
10 showed a normal karyotype, 9 were failures and 4 had an
 
abnormal karyotype and were used as positive controls (Ta-
ble 2). The presence of monosomy Y was not considered as
abnormality (cases 5 and 6).
CGH was performed according to Kallioniemi et al. [11]
with some modifications, as previously described [14].
AP-PCRs were performed in 15 
 

 
l of reaction containing
40, 60, or 80 ng of genomic DNA, 1
 

 
M of an arbitrary
primer, 1 unit of Taq DNA polymerase (Perkin-Elmer/Ce-
tus), 125 
 

 
M each of four dNTPs, 10 mM Tris HCl (pH
8.3), 1.5 
 

 
Ci of [
 

 
-
 
32
 
P]dCTP (3000 Ci/mmol), 50 mM KCl,
4.5 mM MgCl
 
2
 
, and 0.1% gelatin. Amplification was per-
formed in a PTC 100 thermal cycler (MJ Research) for the
first five cycles under low-stringency conditions (at 94
 

 
C
for 30 s, 50
 

 
C for 1 min, and 72
 

 
C for 1.5 min), and then for
25 cycles under high-stringency conditions (at 94
 

 
C for 15
s, 60
 

 
C for 15 s, and 72
 

 
C for 1 min). PCR products were
subjected to electrophoresis in a 5.5% denaturing polyacril-
amide gel. The MCG1 and BLUE arbitrary primers used in
this study had been previously described [12].
FISH was performed in 16 cases in which fixed cells
were available. The presence of trisomy 12 was assessed by
using a probe specific for the centromeric region of chromo-
some 12, D12Z3. To identify 13q14 deletions we used the
LSI D13S25 probe (Vysis, Downers Grove, IL, USA). At
least 200 cells were evaluated in each case.
 
3. Results and discussion
 
The proportion of patients with stage A B-CLL and chro-
mosomal changes increased from 17% (4/23 cases) detected
by conventional G-banding to 43% (10 cases) detected by
CGH, and 62% (15 cases) by AP-PCR. The use of CGH
combined with AP-PCR allowed to detect genetic abnor-
malities in 79% of cases (15/19) with apparently normal or
unsuccessful karyotype (Table 2). As has been reported in
previous studies using FISH, in our series losses of 13q and
gains of chromosome 12 were the most frequent changes
both by CGH and by AP-PCR [1,4–10]. These results were
confirmed by FISH. Besides, these DNA-based techniques
allowed to detect several new abnormalities in addition to
other recurrent changes.
 
3.1. CGH analysis
 
CGH showed a number of recurrent unbalances as fol-
lows: loss of chromosomal material on 13q (four cases), 6q
(two cases), and 5q (two cases); and gain of chromosomal
material on 12q (three cases, two with trisomy 12) and of
the chromosomes 17 and 19 (two cases each). Other unbal-
ances of chromosomal regions detected in single cases
were: loss of 4q, 7p, 11q, 14q, 15q, 17p, 18q, and Xq, and
gain on 1p and 3q. Detailed data of CGH results compared
to cytogenetics and AP-PCR is shown in Table 2. Examples
of most significant changes are shown in Fig. 1.
CGH was more sensitive than G-banding to detect gains
of chromosome 12. Three cases with gains on chromosome
 
Table 1
Clinical features of 23 B-CLL patients at diagnosis
Age median (range) 66 (42–87)
Sex
Male 18
Female 5
Stage Binet/Rai
A/0 14
A/I 9
No. of lymphocytes in blood
 

 
30.000/mm
 
3
 
20
 

 
 30.000/mm
 
3
 
3
Morphology
Typical 21
Atypical 2
Histopathological findings
Nondiffuse infiltration of BM 20
Diffuse infiltration of BM 3
Clinical course
Stable 18
Progression/exitus 5
 10
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12 were identified by CGH, while only one of them had tri-
somy 12 by G-banding. In two of these patients gains were
complete trisomy 12. The third patient had a partial trisomy
with gain on 12q11
 

 
q21 (Fig. 1), a region containing the
 
MDM
 
-2 (murine double minute 2) gene, which has been im-
plicated as a relevant target within the trisomy. 
 
MDM
 
-2 en-
codes an oncoprotein that operates in an autoregulatory
feedback loop with the tumor suppressor protein p53. Am-
plification of the 
 
MDM
 
-2 gene leads to over-expression of
the protein that inactivates p53. Over-expression of 
 
MDM
 
-2
RNA and of several 
 
MDM
 
-2 proteins have been detected in
CLL. Findings in our patient support the importance of this
specific region in B-CLL [1,15,16].
Deletions or translocations of chromosome 13 are the
most common structural abnormalities in B-CLL. Molecu-
lar studies have demonstrated a high incidence of genetic
loss, which is frequently homozygous, telomeric to the 
 
RB1
 
gene, indicating the site of a potential tumor suppressor
gene involved in the pathogenesis of CLL [17,18]. In our
study, del(13q) was the most common aberration detected
by CGH (four cases), although 13q14 band was only in-
volved in two of them. Deletion of chromosome 13 was
missed by conventional cytogenetics in all samples.
CGH detected loss of chromosomal material on 5q, 7p,
11q, 13q (two cases), and 15q in 8 cases with normal or un-
successful karyotype. Two patients had multiple aberrations
(cases 5 and 7), one together with 
 

 
12 and another with
del(13q). Furthermore, CGH revealed some additional ab-
normalities in 2 patients with an abnormal G-banded kary-
otype. In case 1, the chromosomal origin of a marker chro-
mosome could be probably matched with the gain of
chromosome 12 (12q11
 

 
q21) detected by CGH. In the other
(case 3), G-banding detected dup(13q), while CGH also
showed an interstitial deletion on 5q and 13q and gains of
the whole chromosomes 17 and 19. FISH confirmed the
del(13q). Although the duplication on chromosome 13
could be material from chromosome 17 or 19, unresolved
chromosomal aberrations, such as marker chromosomes,
could not completely explain the differences between CGH
and karyotyping. A likely explanation for the discrepancies
is that the methods analyze different cell populations [19].
Three previous CGH studies have been published on
characterization of the genetic changes in CLL [6,20,21]
and only two compared CGH with G-banding results [6,20].
Bentz et al. [20] found aberrations in 50% of normal or not
evaluable cases (9/18) whereas Karhu et al. [6] documented
concordant results between karyotyping and CGH, with
only one abnormal CGH of 13 patients with normal
G-banding. Our study shows that CGH is useful to detect
genetic abnormalities in cases in which G-banding did not
provide information.
 
3.2. AP-PCR analysis
 
This is the first study in samples from patients with CLL
using AP-PCR. The use of primers MCG1 and BLUE gen-
erates a total number of 45 bands with known chromosomal
localization, representing the entire human genome with the
 
Table 2
Results of CGH and AP-PCR analysis in 23 patients with B chronic lymphoid leukemia at diagnosis
CGH AP-PCR
Case G-banding analysis Gains Losses Gains Losses
1 46,XY[6]/48,XY,t(2;14)(p13;q32),
 

 
10,
 

 
3mar[20] 12q11
 

 
q21 17p11
 

 
pter Not evaluable
2 47,XX,
 

 
12[30] 12 12,13q14 N
3 46,XY,dup(13)(q12q13)[32] 17,19 5q15
 

 
q23,13q21
 

 
q31 N N
4 46,XY[6]/46,XY,del(6)(q14q21)[16]/45,idem,
 

 
Y[24] 6q14
 

 
q23 N N
5 46,XY/45,X,
 

 
Y 12 14q21
 

 
q31 12 N
6 46,XY/45,X,
 

 
Y N 12 N
7 46,XY 1p33
 

 
p36,17,19 4q23
 

 
q32,6q13
 

 
q24,13q21
 

 
q32, 9q22 N
18q12
 

 
q22,Xq21
8 46,XX N N N
9 46,XY N 12,13q31 N
10 46,XY N Not evaluable
11 46,XY N N N 13q14
12 46,XX N N N 2,13q14
13 46,XY N N N 9q22
14 46,XY N N N N
15 46,XY N N N N
16 Not evaluable 3q26
 

 
29 15q26 N N
17 Not evaluable 5q15
 

 
q22,7p13
 

 
p21,13q14
 

 
q22 8q24 7,13q14
18 Not evaluable 13q14
 

 
q21 N 11,13q14
19 Not evaluable 11q14
 

 
q23 9q22 11
20 Not evaluable N N 13q14
21 Not evaluable N 11 N
22 Not evaluable N 12 13q14
23 Not evaluable N 12 N
N: Normal
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exception of chromosomes 19, 21 and Y [12]. Table 2 sum-
marizes the genetic alterations detected after the amplotype
analysis using these two arbitrary primers. A representative
result of these experiments is shown in Fig. 2, which high-
lights the regions of the amplotype gel containing bands ex-
hibiting consistent changes in these leukemia samples. De-
termination of losses and gains was carried out by visual
inspection and densitometric analyses [12]. The interpreta-
tion of chromosome losses and gains was based by compar-
ing leukemic DNA fingerprints with several DNA prepara-
tions from normal tissues, and with the previous
accumulative DNA data from many normal tissues. Inten-
sity changes of some bands such as band I (Fig. 2) were not
considered for the analysis because of their polymorphic na-
ture in the human population. However, determination of
losses or gains was possible with the fingerprint bands that
showed no major fluctuations in their intensities among
these normal tissue DNA preparations.
Amplotyping analysis in our series allowed detection of
genomic changes in over two-thirds (15/23) of patients. The
most recurrent alterations were also loss of chromosome 13
sequences in 6 cases (26%) and gain of chromosome 12 se-
quences in 6 cases (26%). MCG1 band J was responsible for
the detection of common losses of chromosome 13 se-
Fig. 1. CGH analysis of B-CLL. Partial karyotypes (left) and corresponding ratio profiles (right) observed in five cases. (A) Case 1 showed an amplified
region on chromosome 12 at band 12q11q21 and loss of 17p. (B) Interstitial deletions in chromosomes 5 and 13 detected in case 17. (C) Loss of chromo-
somal material on 6q in case 4. (D) del(11)(q14q22) detected as a single change in case 19. (E) Partial karyotype observed in case 12. Loss of 13q was found
to be not significant by the software using the threshold 0.8/1.2.
 12
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quences (with the exception of case 1 (Table 2). In contrast,
no losses were detected of band E from the AP-PCR finger-
prints with the same MCG1 primer (data not shown). Sub-
chromosomal localization of these two bands using Gene-
Bridge 4 Radiation Hybrid panels indicated that band E is
located at 13q31
 

 
q32 and band J is more centromeric
(13q14.1
 

 
q14.3). Therefore, band J, but not band E is lo-
cated in the region close to the common region of loss iden-
tified for CLL, as mentioned. Other recurrent changes were
allelic losses of chromosomes 11 (cases 18 and 19), and
gains of 9q22 sequences (cases 7 and 19) (Table 2).
AP-PCR was more informative than CGH for detecting
genetic changes in B-CLL (62% vs 43% of abnormal cases,
respectively) (Table 2). This might be because the amplo-
type is a PCR-based technique that is able to detect alter-
ations in chromosomal regions, which are too small to be
detected by CGH. The sensitivity of the CGH analysis de-
pends on the size of the gain or loss, and on the contamina-
tion of the sample with normal cells [22,23]. The resolution
for the detection of high-copy number amplifications using
CGH has been defined around 2 Mbp. However, only dele-
tions to a size of 10–12 Mbp can be detected based on a di-
agnostic threshold value of 0.8, if the vast majority of cells
carried the deletion [21]. Interestingly, we detected del(13q)
in four patients (cases 11, 12, 20, and 22) using AP-PCR
and these results were confirmed by FISH. These patients
had also loss on 13q by CGH, although the software did not
detect this aberration as significant using the threshold 0.8/
1.2 (Fig. 1E). The power of AP-PCR is limited because it
does not cover the entire genome. This limitation can be in
principle ovecome by the use of additional arbitrary primers
yielding amplotypes with a higher density of informative
chromosomal loci. The discrepancies between the findings
in both techniques indicate the need to be used in a comple-
mentary way. Although CGH is less sensitive than AP-
PCR, the technique is easier and it offers a more complete
scope of genetic changes in the whole genome of the tumor.
In conclusion, the application of CGH and AP-PCR pro-
vides new information on gains and losses of chromosomal
regions in B-CLL that can be especially useful in cases in
which conventional cytogenetics do not provide data on
karyotypic abnormalities. In our series, CGH and AP-PCR
allowed for the characterization of the abnormalities in 79%
of cases with normal or not evaluable karyotype. Our study
using DNA-based techniques confirms that gains of chro-
mosome 12 and loss of 13q, as detected by FISH, are the
most common abnormalities, and that in several cases these
aberrations are not the sole abnormality in the karyotype.
Fig. 2. AP-PCR DNA fingerprinting analysis of B-CLL. Patient identification number is indicated at the top. DNA from normal colon tissue was used as a
diploid control (see text). Two lanes were loaded from each case corresponding to AP-PCR reactions with 40 and 60 ng of genomic DNA. Numbers at the left
indicate the chromosomal origin of the bands named by letters at the right. Changes in the intensity of band G indicate genetic dosage of chromosome X,
which identifies the gender of the patients. BAND I from chromosome 7 is polymorphic in the human population, affecting to the primer annealing site, and,
therefore, in the absence of matching normal tissue, changes of this band cannot be considered for karyotyping purposes. Cases 17, 18, and 22 show loss of
band J at 13q14. Band S on chromosome 12 is represented by two polymorphic alleles with different length. Cases 2 and 5 are heterozygous for this polymor-
phism and show gain of the lower allele in case 2 and gain of the upper allele in case 5. These gains can be detected also in band K from the Blue primer
derived from chromosome 12.
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Both CGH and AP-PCR might also be useful in the detec-
tion of complex karyotypes, which seem to have a clinical
impact [4], and could contribute to the future discovery of
more specific genetic markers for B-CLL. Other studies in a
larger number of patients are required to determine recur-
rent abnormalities with prognostic significance.
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